Esperion Therapeutics, Inc. (ESPR): Price and Financial Metrics


Esperion Therapeutics, Inc. (ESPR)

Today's Latest Price: $51.04 USD

0.66 (-1.28%)

Updated Jul 10 4:00pm

Add ESPR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

ESPR Stock Summary

  • With a price/sales ratio of 294.59, Esperion Therapeutics Inc has a higher such ratio than 98.59% of stocks in our set.
  • With a year-over-year growth in debt of 17,046.21%, Esperion Therapeutics Inc's debt growth rate surpasses 99.48% of about US stocks.
  • Revenue growth over the past 12 months for Esperion Therapeutics Inc comes in at -96.71%, a number that bests only 0.68% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ESPR, based on their financial statements, market capitalization, and price volatility, are ETON, SNDX, CLSN, OTIC, and DCPH.
  • Visit ESPR's SEC page to see the company's official filings. To visit the company's web site, go to www.esperion.com.
ESPR Daily Price Range
ESPR 52-Week Price Range

ESPR Stock Price Chart Technical Analysis Charts


ESPR Price/Volume Stats

Current price $51.04 52-week high $76.98
Prev. close $51.70 52-week low $24.82
Day low $51.01 Volume 232,379
Day high $52.40 Avg. volume 768,597
50-day MA $45.25 Dividend yield N/A
200-day MA $46.47 Market Cap 1.41B

Esperion Therapeutics, Inc. (ESPR) Company Bio


Esperion Therapeutics is focused on developing and commercializing first-in-class, oral, LDL-cholesterol-lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. The company was founded in 1998 and is based in Ann Arbor, Michigan.


ESPR Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ESPR Latest Social Stream


Loading social stream, please wait...

View Full ESPR Social Stream

Latest ESPR News From Around the Web

Below are the latest news stories about Esperion Therapeutics Inc that investors may wish to consider to help them evaluate ESPR as an investment opportunity.

Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bempedoic acid) Tablets

ANN ARBOR, Mich., July 01, 2020 -- Esperion (NASDAQ: ESPR) today announced that pooled efficacy analysis from the four Phase 3 clinical studies of NEXLETOL, an oral, once-daily.

Yahoo | July 1, 2020

Esperion Therapeutics, Inc. (ESPR): Hedge Funds Are Getting Bullish

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

Yahoo | June 23, 2020

Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement

Esperion (ESPR) announced the completion of an amendment to the EU commercial collaboration agreement with Daiichi Sankyo Europe (DSE). Earlier this month, Esperion completed the transfer to DSE of Marketing Authorization Approvals (MAA) for NILEMDO and NUSTENDI.

Yahoo | June 22, 2020

The Play On Esperion Therapeutics

Never underestimate the appeal of stupidity said with conviction." - Kevin Focke Today, we revisit Esperion Therapeutics (ESPR) we had as an option play of the week in mid-November to Biotech Forum members exclusively via a simple covered call strategy. The shares shot up from $40 to $70 in a...

Bret Jensen on Seeking Alpha | June 19, 2020

Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessions

ANN ARBOR, Mich., June 14, 2020 -- Esperion (NASDAQ: ESPR) today announced that pooled analysis from four Phase 3 clinical studies of NEXLETOL were presented at the American.

Yahoo | June 14, 2020

Read More 'ESPR' Stories Here

ESPR Price Returns

1-mo 17.39%
3-mo 42.69%
6-mo -12.51%
1-year 12.15%
3-year 7.57%
5-year -44.30%
YTD -14.41%
2019 29.63%
2018 -30.13%
2017 425.88%
2016 -43.76%
2015 -44.96%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.858 seconds.